Definition of a pharmacophore for partial agonists of serotonin 5-HT3 receptors

Journal of Chemical Information and Computer Sciences

Volumn 39, Issue 2, 1999, Pages 362-369

  Daveu, Cyril ^a   Bureau, Ronan ^a   Baglin, Isabelle ^a   Prunier, Hervé ^a   Lancelot, Jean Charles ^a   Rault, Sylvain ^a  

^a UNIVERSITÉ DE CAEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN 3 RECEPTOR; SEROTONIN AGONIST; SEROTONIN RECEPTOR;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER PROGRAM; DRUG EFFECT; DRUG SCREENING; ELECTRICITY; IN VITRO STUDY; STRUCTURE ACTIVITY RELATION;

DRUG EVALUATION, PRECLINICAL; ELECTROSTATICS; MODELS, MOLECULAR; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN AGONISTS; SOFTWARE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033088232     PISSN: 00952338     EISSN: None     Source Type: Journal    
DOI: 10.1021/ci980153u     Document Type: Article

References (42)

1. Martin, G. R.; Humphrey P. P. Receptors for 5-Hydroxytryptamine: Current Perspectives on Classification and Nomenclature. Neuropharmacology 1994, 33, 261-273.
2. Hoyer, D.; Clarke, D. E.; Fozard, J. R.; Harting, P. R.; Martin, G. R.; Mylecharane, E. J.; Saxena, P. R.; Humphrey, P. P. VII International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine (Serotonin). Pharmacol. Rev. 1994, 46, 157-203.
3. Zifa, E.; Fillion, G. 5-Hydroxytryptamine Receptors. Pharmacol. Rev. 1992, 44, 401-458.
4. Saxena, P. R. Serotonin Receptors: Subtypes, Functional Responses and Therapeutic Relevance. Pharmacol. Ther. 1995, 66, 339-368.
5. Sanger, G. J.; Nelson, G. R. Selective and Functional 5-Hydroxytryptamine Receptor Antagonism by BRL 43694 (Granisetron). Eur. J. Pharmacol. 1989, 159, 113-124.
6. 3 Receptors. Br. J. Pharmacol. 1988, 94, 387-412.
7. Richardson, B. P.; Engel G.; Donatsch, P.; Stadler, P. A. Identification of Serotonin M-Receptor Subtypes and Their Specific Blockade by a New Class of Drugs. Nature 1985, 316, 126-131.
8. 3 Receptor Antagonists. An Overview of Their Present Status and Future Potential in Cancer Therapy-Induced Emesis. Drugs 1991, 42, 551-568.
9. 3 Receptors. Part 1. Synthesis and Biological Evaluation of Piperazinopyrrolothienopyrazines. J. Med. Chem. 1996, 39, 2068-2080.
10. 3 Receptor Agonists. Eur. J. Pharmacol. 1990, 182, 193-197.
11. Higgins, G. A.; Joharchi, N.; Sellers, E. M. Behavioural Effects of the 5-Hydroxytryptamine3 Receptor Agonists 1-Phenyl Biguanide and m-Chlorophenylbiguanide in Rats. J. Pharmacol. Exp. Ther. 1993, 264, 1440-1449.
12. 3H]-Granisetron. Biochem. Pharmacol. 1993, 45, 2155-2158.
13. 3H]-GR 65630 Binding. Br. J. Pharmacol. 1991, 102, 919-925.
14. Glennon, R. A.; Ismael, A. M.; McCarthy, B. G.; Peroutka, S. J. Binding of Arylpiperazines to 5-HT3 Serotonin Receptors: Results of the Structure Affinity Study. Eur. J. Pharmacol. 1989, 168, 387-392.
15. 3 Receptor Ligands and Substance P. J. Neurochem. 1993, 60, 2059-2061.
16. 3 Receptors. Quant. Struct.-Act. Relat. 1996, 15, 373-381.
17. 3 Receptors. Part 2. Synthesis and Biological Evaluation of Piperazinopyridopyrrolopyrazines, Piperazinopyrroloquinoxalines, and piperazinopyridopyrroloquinoxalines. J. Med. Chem. 1997, 40, 1808-1819.
18. Rault, S.; Robba, M.; Lancelot, J. C.; Prunier, H.; Renard, P.; Pfeiffer, B.; Guardiola, B.; Rettori, M. C. Nouveaux ethers d'oximes tricycliques, leurs procédés de fabrication et les compositions pharmaceutiques qui les contiennent. Eur. Pat. Appl. 9415431, 1994.
19. Catalyst, version 3.0; Molecular Simulations Inc.: Burlington, MA, 1993.
20. Sprague, P. In Perspectives in Drug Discovery and Design; Anderson, P. S.; Kenyon, G. L.; Marshall, G. R.; Müller, K., Eds.; ESCOM: Leiden, 1995; Vol. 3, Chapter 1, pp 1-20.
21. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; Sates, D. J.; Swaninathan, S.; Karplus, M. CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations. J. Comput. Chem. 1983, 4, 187-217.
22. Smellie, A.; Teig, S. L.; Towbin, P. Poling: Promoting Conformational Variation. J. Comput. Chem. 1995, 16, 171-187.
23. Cosulich, D. B.; Lovell, F. M. The X-ray Crystal Structures of Loxapine (2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine) and Amoxapine (2-chloro-11-(1-piperazinyl)dibenz[b,f][1,4]-oxazepine). Acta Crystallogr., Sect. B 1977, 33, 1147-1150.
24. Fillers, J. P.; Hawkinson, S. W. The structure of 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine Dihydrobromide, Clozapine Dihydrobromide. Acta Crystallogr., Sect. B 1982, 38, 1750-1753.
25. Fillers, J. P.; Hawkinson, S. W. The structure of 4-(2-chlorodibenz-[b,f][1,4]oxazepin-11-yl)-1-methyl-piperazinium Succinate Monohydrate (Loxapine Succinate Monohydrate). Acta Crystallogr., Sect. B 1982, 38, 3041-3045.
26. Steiner, G.; Franke, A.; Hadicke, E.; Lenke, D.; Teschendorf, H. J.; Hoffmann, H. P.; Kreiskott, H.; Worstmann, W. Tricyclic epines. Novel (E)-and (Z)-11H-dibenz[b,e]azepines as Potential Central Nervous System agents. Variation of the basic side chain. J. Med. Chem. 1986, 29, 1877-1888.
27. Alabaster, V. A.; Campbell, S. F.; Danilewicz, J. C.; Greengrass, C. W.; Plews, R. M. 2,4-Diamino-6,7-dimethoxyquinazolines. 2. 2-(4-Carbamoylpiperidino) Derivatives as Alpha I-Adrenoreceptor Antagonists and Antihypertensive Agents. J. Med. Chem. 1987, 30, 999-1003.
28. Dupont, L.; Dideberg, O.; Liegeois, J.-F.; Delarge, J. Structure du maléate de méthyl-1(pyrido[2,3-f][1,5]benzoxazepinyl-5)pipérazinium. Acta Crystallogr., Sect. C (Cr. Str. Comm.) 1987, 43, 716-719.
29. Sbit, M.; Dupont, L.; Dideberg, O.; Liegeois, J.-F.; Delarge, J. Structure de la clothiapine. Acta Crystallogr., Sect. C (Cr. Str. Comm.) 1987, 43, 720-722.
30. Sbit, M.; Dupont, L.; Dideberg, O.; Liegeois, J.-F., Delarge, J. Structure du (méthyl-1 pipérazinyl-4)-5pyrido[2,3-b][1,5]benzothiazépine. Acta Crystallogr., Sect. C: Cryst. Struct. Commun. 1988, 44, 319-322.
31. Dupont, L.; Dideberg, O.; Liegeois, J.-F.; Delarge, J. Structure du (méthyl-4 pipérazinyl-1)-10 pyrido[4,3-b][1,4]benzothiazépine. Acta Crystallogr., Sect. C: Cryst. Struct. Commun. 1991, 47, 1740-1742.
32. Dupont, L.; Englebert, S.; Dideberg, O.; Liegeois, J.-F.; Delarge, J. Structures du 11-Formyl-5-(4-methylpipérazin-1-yl)-11H-pyrido[2,3-b][1,5] benzodiazépine et du 6-(4-Methylpipérazin-1-yl)-11-méthyl-11H-pyrido [2,3-b][1, 4]benzodiazépine. Acta Crystallogr., Sect. C: Cryst. Struct. Commun. 1991, 47, 2690-2692.
33. Dupont, L.; Englebert, G.; Dideberg, O.; Liegeois, J.-F.; Delarge, J. Structure du 8-chloro-11-(4-methylpipérazin-1-yl)dibenzo[b, f][1,4]-thiazépine. Acta Crystallogr., Sect. C: Cryst. Struct. Commun. 1992, 48, 1851-1853.
34. 3 Receptor Antagonists and a Definition of a Model for This Receptor Site. J. Med. Chem. 1990, 33, 1594-1600.
35. UNICHEM, version 3.0; Cray Research, Inc. 1995.
36. Fisher, R. The Design of Experiments; Hafner Publishing: New York, 1966; Chapter 2.
37. LUNDON2; Lundon Software, Inc.: http://www.geocities.com.
38. Antolini, L.; Menabue, L.; Pellacani, G. C.; Saladini, M.; Marcotrigiano, G. Bis(N-Benzylpiperazinium chloride) Tetrachloro-Copper-(ii). Inorg. Chim. Acta 1982, 58, 193-196.
39. Menabue, L.; Pellacani, G. C.; Albinati, A.; Ganazzoli, F.; Cariati, F.; Rassu, G. N-(2-Ammoniumethyl)-piperazinium monochloride tetrachloro-mercury(ii). Inorg. Chim. Acta 1982, 58, 227-230.
40. DISCOVER 95.0/3.00 software; Molecular Simulations Inc.: Burling-ton, MA, 1993.
41. Amit, A.; Mester, L.; Klewe, B.; Fürberg, S. Acta Chem. Scand. Ser. A 1978, 32, 267-269.
42. Allen, F. H.; Kennard, O. Chemical Design Automation News 1993, 8, 31-37.